NEW YORK — The drug and medical device maker Covidien has closed its $2.6 billion acquisition of endovascular surgery device maker ev3 Inc.
Covidien on June 1 unveiled plans to buy the company for $22.50 per share — at the time, a 19 percent premium.
In a statement yesterday, Covidien said it tendered just over 100.8 million shares of ev3 stock, representing about 87.7 percent of outstanding shares. Covidien said COV Delaware Corp. then exercised its option to buy newly issued shares from ev3 at the tender offer price, allowing Covidien to complete the buyout.
Covidien, based in Dublin, Ireland, has US headquarters in Mansfield, Mass.
Ev3 makes devices used in endovascular surgeries, or operations in which surgeons make small incisions and maneuver devices through major blood vessels. The company, based in Plymouth, Minn., will become part of Covidien’s vascular products business.
US-traded Covidien shares fell 28 cents to close at $40.48.